Technology Transfer

Our work is done in collaboration with, or under the expert advice of renowned clinicians and key opinion leaders, and some of the most important worldwide Pharma players (Eli-Lilly, Merck, Alnylam, GKS, Pharmamar, NovoNordisk) so as to be up to date with the unmet medical needs and benchmarks, as well as with the drug and industry trends in our field.

Our translational vision is underlined by the filing for 23 patent families, the licensing-out of most of these inventions to pharma biotech companies, and the establishment of strong alliances.

Currently we are collaborating with:

ELI LILLY (2024-2027) Eli Lilly and Company - Wikipedia, la enciclopedia libre
ALNYLAM (2023-2027) Alnylam envía una solicitud regulatoria a la Agencia Europea de Medicamentos por vutrisiran para el tratamiento de amiloidosis con cardiomiopatía
QUANTUM BIOSCIENCES (2023-2027)  Quantum Biosciences
CERTEST (2023-25)  Certest Biotec - Arahealth
PHARMAMAR (2023-25) PharmaMar - Wikipedia, la enciclopedia libre

Finally, the lab has promoted the creation of two start-up companies:

LIBERA-BIO (2019 to present) https://www.liberabio.com

Libera Bio | Addressing undruggable intracellular targets in oncology
SMART VITAMINS (2019 to present) http://smartvitamins.org

smartvitamins.org – smartvitamins.org

CONTACT

Phone: (34) 881815454
E-Mail: mariaj.alonso@usc.es
Mailing Address:
CIMUS Research Institute
Avda. de Barcelona s/n
Campus Vida s/n
15782, Santiago de Compostela

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.